130 related articles for article (PubMed ID: 28024110)
1. The importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions.
Sadullahoglu C; Nart D; Veral A
Diagn Cytopathol; 2017 Feb; 45(2):118-124. PubMed ID: 28024110
[TBL] [Abstract][Full Text] [Related]
2. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
4. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.
Oda T; Ogata S; Kawaguchi S; Minabe S; Dokyu M; Takahashi H; Kumazawa F; Shimazaki H; Takano M; Hase K; Ozeki Y; Kanoh S; Nakanishi K
Diagn Cytopathol; 2016 Jun; 44(6):499-504. PubMed ID: 27015745
[TBL] [Abstract][Full Text] [Related]
6. Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer.
Lv M; Leng JH; Hao YY; Sun Y; Cha N; Wu GP
Diagn Cytopathol; 2015 Jul; 43(7):527-31. PubMed ID: 25346242
[TBL] [Abstract][Full Text] [Related]
7. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
8. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
9. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
10. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
11. Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
Hiroshima K; Wu D; Hasegawa M; Koh E; Sekine Y; Ozaki D; Yusa T; Walts AE; Marchevsky AM; Nabeshima K; Tada Y; Shimada H; Tagawa M
Diagn Cytopathol; 2016 Jul; 44(7):591-8. PubMed ID: 27079839
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
14. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
17. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
Rehnberg J; Zendehrokh N; Dejmek A
Anal Quant Cytol Histol; 2007 Aug; 29(4):217-20. PubMed ID: 17879629
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of Claudin-4 and EZH2 Immunohistochemistry in Effusion Cytology.
Elhosainy A; Hafez MMA; Yassin EH; Adam M; Elnaggar MS; Aboulhagag NA
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2779-2785. PubMed ID: 36037134
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
20. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
